PlumX Metrics
Embed PlumX Metrics

Cancer immunotherapy via dendritic cells

Nature Reviews Cancer, ISSN: 1474-175X, Vol: 12, Issue: 4, Page: 265-277
2012
  • 1,688
    Citations
  • 0
    Usage
  • 1,933
    Captures
  • 4
    Mentions
  • 238
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    1,688
    • Citation Indexes
      1,680
    • Patent Family Citations
      7
      • Patent Families
        7
    • Policy Citations
      1
      • Policy Citation
        1
  • Captures
    1,933
  • Mentions
    4
    • News Mentions
      2
      • News
        2
    • References
      2
      • Wikipedia
        2
  • Social Media
    238
    • Shares, Likes & Comments
      238
      • Facebook
        238

Most Recent News

DENV Peptides Delivered as Spherical Nucleic Acid Constructs Enhance Antigen Presentation and Immunogenicity in vitro and in vivo

Introduction Dengue virus (DENV), a member of the flavivirus genus within the Flaviviridae family, is a single-stranded, positive-sense RNA virus primarily transmitted by Aedes aegypti

Review Description

Cancer immunotherapy attempts to harness the power and specificity of the immune system to treat tumours. The molecular identification of human cancer-specific antigens has allowed the development of antigen-specific immunotherapy. In one approach, autologous antigen-specific T cells are expanded ex vivo and then re-infused into patients. Another approach is through vaccination; that is, the provision of an antigen together with an adjuvant to elicit therapeutic T cells in vivo. Owing to their properties, dendritic cells (DCs) are often called 'nature's adjuvants' and thus have become the natural agents for antigen delivery. After four decades of research, it is now clear that DCs are at the centre of the immune system owing to their ability to control both immune tolerance and immunity. Thus, DCs are an essential target in efforts to generate therapeutic immunity against cancer. © 2012 Macmillan Publishers Limited. All rights reserved.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know